Portola Pharmaceuticals Inc. - South San Francisco, Calif., 6.9 million shares, priced $13 to $16, managed by Morgan Stanley and Credit Suisse. Proposed Nasdaq symbol PTLA. Business: Developing a blood thinner and a novel reversal agent for acutely ill patients.
Description
Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options. The Company’s two lead programs address unmet medical needs in the area of thrombosis, or blood clots. The Company’s lead compound Betrixaban is an oral once-daily inhibitor of Factor Xa in Phase III development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism (VTE), in acute medically ill patients. The Company’s third product candidate, PRT2070, is an orally available kinase inhibitor being developed for hematologic, or blood, cancers and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase (Syk), and janus kinases (JAK), enzymes that regulate signaling pathways.
Portola Pharmaceuticals is led by CEO William Lis
Address
270 E. Grand Avenue
SOUTH SAN FRANCISCO, CA 94080
United States
+1-650-2467000 (Phone)
+1-650-2467376 (Fax)
SOUTH SAN FRANCISCO, CA 94080
United States
+1-650-2467000 (Phone)
+1-650-2467376 (Fax)
Website
www.portola.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -830.37% | 15.78% |
| Operating margin | -843.52% | 15.07% |
| EBITD margin | - | 17.00% |
| Return on average assets | -45.67% | 6.70% |
| Return on average equity | -3013.20% | - |
| Employees | 57 |
No comments:
Post a Comment